Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases
Top Cited Papers
Open Access
- 1 April 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (7), e61-e65
- https://doi.org/10.1086/500212
Abstract
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n = 81) or were intolerant of such treatment (n = 10) and participated in the compassionate-use posaconazole (800 mg/day) program. The rate of success (i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.This publication has 16 references indexed in Scilit:
- Posaconazole as Salvage Therapy for ZygomycosisAntimicrobial Agents and Chemotherapy, 2006
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Zygomycosis in a Tertiary‐Care Cancer Center in the Era ofAspergillus‐Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent CasesThe Journal of Infectious Diseases, 2005
- Zygomycosis (mucormycosis): emerging clinical importance and new treatmentsCurrent Opinion in Infectious Diseases, 2004
- Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infectionsInternational Journal of Clinical Practice, 2004
- Mucormycosis (Zygomycosis) in a Heart-Kidney Transplant Recipient: Recovery after Posaconazole TherapyClinical Infectious Diseases, 2003
- In Vivo Activity of Posaconazole againstMucorspp. in an Immunosuppressed-Mouse ModelAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of ZygomycetesAntimicrobial Agents and Chemotherapy, 2002
- Zygomycosis in the 1990s in a Tertiary-Care Cancer CenterClinical Infectious Diseases, 2000
- Zygomycetes in Human DiseaseClinical Microbiology Reviews, 2000